# CHRYSALIS

Source: https://onco.cc/trials/chrysalis/  
OnCo record `chrysalis` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CHRYSALIS was the first human study of amivantamab, an antibody that grabs both EGFR and MET; its cohort of people with EGFR exon 20 insertion lung cancer responded well enough to earn the drug its first approval.

## Summary

CHRYSALIS is the phase 1 dose-escalation and expansion study of amivantamab, a bispecific antibody against EGFR and MET, in advanced non-small-cell lung cancer. Expansion cohorts tested the antibody alone in EGFR exon 20 insertion disease after platinum chemotherapy, and in combination with the third-generation EGFR inhibitor lazertinib or with chemotherapy in other EGFR-mutant settings.

The exon 20 insertion cohort, a group for which conventional EGFR inhibitors work poorly, showed a clinically meaningful response rate with durable responses, and amivantamab received accelerated approval in the United States in May 2021 for that indication. The combination cohorts with lazertinib provided the rationale for the phase 3 MARIPOSA and MARIPOSA-2 trials.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-17
- Tags: subtype-trials
- Registry id: NCT02609776
- Phase: 1
- Setting: Advanced non-small-cell lung cancer: first-in-human study of the bispecific EGFR and MET antibody amivantamab alone and with lazertinib or chemotherapy, with expansion cohorts by EGFR alteration
- Sponsor: Janssen Research & Development
- Enrolled: 751
- Result: Amivantamab produced durable responses in EGFR exon 20 insertion non-small-cell lung cancer after platinum chemotherapy; accelerated approval in May 2021.
- Outcomes: Overall response rate, EGFR exon 20 insertion cohort after platinum chemotherapy (FDA approval summary): Amivantamab 40%; Duration of response, EGFR exon 20 insertion cohort: Amivantamab 11.1 months; Infusion-related reactions: Amivantamab 66%

## Sources

- ClinicalTrials.gov NCT02609776: https://clinicaltrials.gov/study/NCT02609776

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/)
- drugs: [Amivantamab](https://onco.cc/drugs/amivantamab/), [Lazertinib](https://onco.cc/drugs/lazertinib/)
- companies: [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)
- people: [Keunchil Park](https://onco.cc/people/keunchil-park/)
- key papers: [Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial](https://onco.cc/key-papers/paper-chrysalis-nat-med-2023/)

---
JSON: https://onco.cc/api/v1/entities/chrysalis.json